Chemical formula: C₂₅H₃₉N₃O₈ Molecular mass: 509.6 g/mol PubChem compound: 114905
Landiolol is a highly selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines adrenaline and noradrenaline on the heart, where beta-1-receptors are predominantly located. Landiolol, as other beta-blockers, is thought to reduce the sympathetic drive, resulting in reduction in heart rate, decrease in spontaneous firing of ectopic pacemakers, slowing the conduction and increase the refractory period of the AV node.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C07AB14 | C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AB Beta blocking agents, selective | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| RAPIBLOC Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Landiolol is an active ingredient of these brands:
Austria (AT)
Croatia (HR)
Estonia (EE)
Finland (FI)
France (FR)
Lithuania (LT)
Netherlands (NL)
Poland (PL)
Romania (RO)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
